Peter Reynolds

The life and times of Peter Reynolds

Posts Tagged ‘Professor Mike Barnes

Let’s Temper Hope For Paul Flynn’s Medical Cannabis Bill With Some Reality.

with 3 comments

Paul Flynn MP introducing his 10 Minute Rule Bill

No one would like to see Paul Flynn’s ‘Elizabeth Brice’ bill  to re-legalise medical cannabis pass through Parliament more than me.  Yet it concerns me that expectations are being raised way beyond what is realistic. There is widespread misunderstanding about what the bill is and what are its chances of getting any further.

The Legalisation of Cannabis (Medicinal Purposes) Bill 2017–19 is a Private Member’s Bill. It was  introduced to Parliament on Tuesday 10 October 2017 under the Ten Minute Rule. This allows an MP to make his or her case for a new bill in a speech lasting up to ten minutes. An opposing speech may also be made before the House decides whether or not the bill should be introduced. If the MP is successful the bill is taken to have had its first reading.

Private Member’s Bills almost never become law.  Those that have the best of a very slim chance are proposed by one of about 20 MPs who win the right to put a bill forward a bill in the ballot that takes place at the beginning of each session.  This also decides the order of precedence for the 20 bills to be given parliamentary time.

A 10 Minute Rule Bill is even less likely to become law.  It is the only way other than the ballot that an MP can introduce a bill personally and if it passes its first reading, as Paul Flynn’s bill did, it is set down for second reading.  All Private Member’s Bills are debated on Fridays and before any 10 Minute Rule can be debated the bills put forward under the ballot will come first and even for those, mostly there will be no time available.  Remember also that on Fridays most MPs will not even be in Parliament, they will be back in their constituencies seeing people in their surgeries.

Sadly, the truth is that the second reading of Paul Flynn’s bill is unlikely even to take place.  Although it is set down for 23rd February 2018, there is virtually zero chance of any time being found for it.  It will simply wither away with no progress or further mention.

Even Parliament’s own website says of 10 Minute Rule Bills “an opportunity for Members to voice an opinion…rather than a serious attempt to get a Bill passed.”

I asked Paul Flynn himself what he thought were the chances of his bill making any progress and his response is illuminating. His exact words were: “I am expecting major changes to political party attitudes in the next 12 months following the developing trends in the United States.”

I think we can all agree on that.  In fact, I would say that there already have been major changes in the attitudes of most MPs.  The single biggest obstacle to any drug law reform is Theresa May. After all, what other leader anywhere in the world, apart from the murderous thug President Durterte of the Philippines, has recently called for a continuance of the war on drugs?

May and Duterte – two of a kind on drugs policy

I am confident that once Theresa May is gone, then whatever party is in power, we will see some progress. There is similar, hopeless optimism about Jeremy Corbyn.  Speaking at a Labour leadership debate in Glasgow, in  August 2016, he said: “I would decriminalise medicinal uses of cannabis.”  I think it was the same day or the day after that both John McDonnell and Diane Abbott contradicted him.   Nevertheless, there is a delusional strand of opinion that Corbyn would act on this immediately he was elected.  Dream on!  The Labour Party has the worst record of any UK political party on drugs policy.  For instance it was Margaret Thatcher who introduced needle exchange back in the 80s and yes, even Theresa May sanctioned the provision of foil to heroin users for smoking as an alternative to injecting.  The Labour Party has never done anything in support of progressive drugs policies that it hasn’t reversed under pressure from the tabloid press.

Progress on access to medical cannabis is coming irrespective of which party is in power.  In the meantime, the best that any of us can do is keep up pressure on our personal MPs and in our local media and through our doctors.  Probably the biggest breakthrough this year on medical cannabis will be the publication of guidelines by the Royal College of General Practitioners (RCGP).  Organised by CLEAR and authored by our Scientific and Medical Advisor, Professor Mike Barnes, this shows MPs that however irresponsible and pig-headed government ministers may be, doctors have a responsibility to their patients, an ethical duty that transcends the grubby and corrupt politics that ministers subscribe to.

Sadly then, 23rd February and the second reading of Paul Flynn’s bill will be a non-event. For the rest of 2018 look out for the RCGP guidelines and drop your MP a line when they come out asking for his or her view.  Also, in July look out for Canada’s legalisation of cannabis for all adults.  Again, another opportunity to bring the subject up with your MP.  The latest, standard, Home Office approved reply from MPs reads as follows:

“Cannabis in its raw form is not recognised as having any medicinal purposes. The licensing regime for medicines is administered by the Medicines and Healthcare products Regulatory Agency (MHRA), which issues licences for medicines in the UK which have been tested for their safety, quality and efficacy. 
 
A medicine derived from the cannabis plant, Sativex, has already been licenced for use in the treatment of spasticity due to multiple sclerosis (MS). The MHRA is open to considering other licence applications for medicines containing cannabinoids should such products be developed.
 
In 2014, the National Institute for Health and Care Excellence (NICE) published its clinical guideline on the management of MS that does not recommend Sativex as a cost effective use of NHS resources. In the absence of positive guidance from NICE, it is for commissioners to make decisions on whether to fund this treatment based on an assessment of the available evidence.
 
I do appreciate that there are people with chronic pain and debilitating illnesses who seek to alleviate their symptoms by using cannabis.  Although such use is illicit, the Sentencing Council’s guidelines on drug offences identify such circumstances as a potential mitigating factor.
 
The Government has no plans to legalise the recreational use of cannabis. The official advice from the Advisory Council on the Misuse of Drugs cites medical and scientific research showing that cannabis use has a number of adverse acute and chronic health effects, especially for people with mental health problems, and continues to present a significant public health issue.”

If you receive this response, first of all, don’t bother writing back, it will get you nowhere.  If you really want to do your bit then make an appointment to see your MP at his/her surgery.  Then give him/her this simple fact that totally devastates the Home Office and MHRA position:

In every jurisdiction throughout the world where medicinal cannabis has been legally regulated, it is through a special system outside pharmaceutical medicines regulation.

This is the government’s very last excuse for denying access to medicinal cannabis. The MHRA process is incapable of dealing with a medicine that contains hundreds of molecules.  It is designed by the pharmaceutical industry for regulating single molecule medicines, usually synthesised in a lab, which have the potential to be highly toxic. Every other government that has recognised the enormous benefit that medicinal cannabis offers has come to the same conclusion: cannabis is a special case.  It is far more complex but much, much safer than pharmaceutical products.

 

Advertisements

Probably The Biggest Breakthrough Yet For Medicinal Cannabis In The UK.

with 2 comments

Peter Reynolds, President, CLEAR Cannabis Law Reform

Since the beginning of 2017, Peter Reynolds and Professor Mike Barnes of CLEAR Cannabis Law Reform have been working on a project that is about to come to fruition.  The Council of the Royal College of General Practitioners (RCGP) meets tomorrow, 22nd September 2017, to consider our proposal to issue guidelines to doctors on the use of medicinal cannabis.

Professor Mike Barnes, Scientific & Medical Advisor, CLEAR Cannabis Law Reform

As ever, the UK’s stubborn, anti-evidence government remains intransigent on permitting legal access to cannabis, even for medicinal use.  This despite an overwhelming tide of reform across the world and the reality that perhaps one million people in the UK are criminalised and persecuted for using a medicine that has been known to be safe and effective for many centuries, facts which modern science now proves beyond doubt.

However irresponsible and pig-headed government ministers may be, doctors have a responsibility to their patients, an ethical duty that transcends the grubby and corrupt politics that ministers subscribe to. Professor Nigel Mathers, Honorary Secretary of the RCGP with responsibility for its governance, has championed CLEAR’s proposal.  He recognises that while doctors cannot be advising their patients to use an illegal drug, the reality is many people already are.

Professor Nigel Mathers, Honorary Secretary, Royal College of GPs

So this is not just another report or a conference.  This is practical action at the point of delivery of healthcare.  If the proposal is approved by the RCGP Council, the guidelines will be drafted by Professor Mike Barnes, assisted by Peter Reynolds, with additional input from the MS Society and Newcastle University.

In due course, probably by the end of the year, a booklet will be available for download by all GPs from the RCGP website.  It will set out balanced and reasonable advice on the appropriate use of cannabis for specific medical indications. The guidelines will also cover harm reduction advice and provide a basic grounding in the scientific evidence and the endocannabinoid system.

If our government refuses to take such sensible steps to improve healthcare and protect patients, then we, campaigners and medical professionals, must do it for them.

 

How To Campaign For Cannabis Law Reform Under A Theresa May Government.

with one comment

  • Lobbying Parliament

  • If the Government Won’t Regulate Cannabis Then We’ll Do It For Them

  • The CBD Market

  • Medical Cannabis

  • Educating And Influencing Researchers

For cannabis and drugs policy reform, out of 650 MPs, there could not have been a worse person to seize power than Theresa May.  There are a few who come close on both Tory and Labour benches but no one who has such a long record of bigotry, denial of evidence and refusal even to consider the subject.

Senior Tory MPs For Cannabis Law Reform

To be fair, I am a member of the Conservative Party, which to many people involved in the cannabis campaign is a mortal sin but my advocacy is based on science and evidence, not tribalism or wider politics.  In any case, though many find this fact hard to accept, there has always been more support from Tory MPs than Labour. Highly influential and senior Tory MPs such as Crispin Blunt, Peter Lilley and Dr Dan Poulter are powerful advocates for reform. I firmly believe that the only sustainable route to legalisation is commercialisation and the left wing, nanny state, anti-business types are already pushing the ‘Big Cannabis’ scare stories.

So what can we do and what are we doing to advance our cause in these dark days?  Theresa May always has been secretive, inaccessible, unresponsive and entirely disinterested in any opinion except her own.  How can we possibly make any progress with a PM who has already shown she is prepared to cover up or falsify evidence and defines herself by her belief in a supernatural power?

There is more support for cannabis law reform in Parliament than ever before.  It is now official policy of both the Liberal Democrats and the Scottish National Party. The support from Scotland is far more valuable than that from the discredited LibDems.  With the added factors of Brexit and Scottish Independence, the SNP is in a powerful position to advance its policies.  Also, in Ireland, both north and south, public support for medical cannabis reform is exploding.  Michelle O’Neill, SinnFein’s new leader, has pledged medical cannabis reform if she is re-elected (though she has no power to do so!).  Her negotiating position is immensely strong now that the problems at Stormont, the rise of Sinn Fein and the Brexit factor all combine to make a united Ireland a real possibility.

During the coalition government from 2010 to 2015, few doors were closed to us.  Over that period, CLEAR conducted more meetings with ministers and senior politicians than the entire UK campaign had achieved in 50 years.  Because we had support from the LibDems, and introductions from the Deputy Prime Minister, even Tory ministers were ready to see us, even if they were merely paying lip service.  That all stopped with the election of a majority Conservative government and after Cameron stepped down the doors were slammed in our faces, bolted and double-locked.  The campaign has been in the doldrums ever since. Or has it?

The last major achievement of the last few year’s campaigning was the release of the APPG report on medical cannabis in September 2016.  Alongside it, Professor Mike Barnes, CLEAR advisory board member, published his review ‘Cannabis: The Evidence for Medical Use‘.  To all impartial and reasonable observers, these documents should have initiated positive government action towards reform, even if it was only very limited in scope.  But no, Theresa May didn’t leave it to Amber Rudd, her successor as home secretary, she stepped straight in herself on the day of publication, before she could even have read it and dismissed the report out of hand.  This echoes the apocryphal story of James Callaghan, then PM, throwing the 1969 Wooton Report in the bin without even opening it.  Such is the inertia and prejudice that has not softened at all amongst the bigots despite 45 years of science and research proving that there are better, safer, more beneficial options available on cannabis.

Lobbying Parliament

For now, individual lobbying of MPs is our only route to power. Over the years we have refined our approach to this and we know what works.  Getting into ping pong correspondence with an MP is a waste of time.  An initial letter or email needs to be followed up with a face-to-face meeting and a determined focus on getting a tangible result. What sort of result you should look for depends on your circumstances but getting your MP to arrange a meeting with a government minister should be your goal.

If you’re a medical user then you’ll want to meet a health minister, preferably the Secretary of State, if not a junior minister or perhaps an advisor to the Department of Health.  Work with your MP to achieve the best result you can.  Your MP doesn’t necessarily have to agree with you about cannabis but they should facilitate your communication with government, that’s their job. If you’re more interested in the economic or social benefits to be gained from reform, you could ask for an introduction to the Chancellor, a treasury or business minister, or someone at the Cabinet Office who is involved in policy development.  CLEAR can usually provide someone to accompany you on meetings but this must be arranged in advance and agreed with your MP or whoever your appointment is with.  Alternatively, we can provide advice over the telephone on how to approach the meeting, what to ask for and what evidence or supporting material to take with you.

If the Government Won’t Regulate Cannabis Then We’ll Do It For Them

With an intransigent government that does it all it can to evade engagement on this issue, there is more that CLEAR is already doing.  If the government won’t take responsibility and regulate cannabis, then step by step we are going to do it for them.  Someone has to, there is far too much harm and suffering caused by present policy.

The CBD Market

Through 2016 the CBD market in the UK really began to take off.  These are products derived from industrial hemp, grown legally under licence that offer many of the therapeutic benefits of cannabis.  They should, in fact, be more accurately termed low-THC cannabis as apart from crystals and a few, rare examples of isolated CBD, they are whole plant extracts and contain all the cannabinoids, terpenes, flavonoids and other compounds found in the plants from which they are made.  Therefore they offer many of the ‘entourage effect’ benefits but with very low levels of THC.  It was obvious though that this market was heading for problems.  More and more dubious suppliers were starting up, many making brazen claims for the medical effects and benefits of their products and many without any product testing, quality assurance or honest customer service.  The law was then and always has been crystal clear, you cannot make medical claims for a product without it being properly licensed or regulated.  Inevitably, in June 2016 the MHRA stepped in and sent threatening letters to a number of CBD suppliers.

CLEAR took the initiative.  We wrote to the MHRA requesting a meeting.  We engaged with the leading CBD suppliers and our advisory board members Professor Mike Barnes and Crispin Blunt MP were quickly on the case.  The story has already been extensively reported but now, nearly a year on, our efforts are coming to fruition. We led the approach to the MHRA and in the process created what is now the Cannabis Trades Association UK (CTAUK).  It is now recognised by the MHRA, it has established a code of conduct and it is now the gold standard of quality, ethics and legality that can give anyone buying CBD products real peace of mind.  There are still cowboys out there, making false claims, selling products that offer no real benefit and even endangering their customers with products that are illegal under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016.  Now though, customers can go to the CTAUK website and choose a supplier that is operating legally, ethically and within the regulations that the industry itself has established.  We expect the MHRA very shortly formally to endorse CTAUK members as legitimate suppliers of CBD products as food supplements.

Medical Cannabis

Professor Nigel Mathers, Honorary Secretary, Royal College of GPs

Neither can we accept the government’s irresponsible and cruel policy towards people who need cannabis as medicine. So CLEAR has taken a further initiative. After Theresa May’s dismissal of the APPG report, we approached the Royal Colleges of medicine.  We pointed out that whatever the government might say, around one million people are using cannabis as medicine.  Doctors have a duty and an ethical responsibility to educate themselves on the subject and be able to provide properly informed care to their patients.  Our efforts have borne fruit.  Professor Mike Barnes and I have worked with Professor Nigel Mathers of the Royal College of GPs (RCGP).  We will be producing a draft set of guidelines on medicinal cannabis for GPs which will go the next meeting of the RCGP Council and is planned for publication in June 2017.  If the government won’t do it, we will and the medical profession agrees with us.  This will be the greatest practical advance ever made in medical cannabis in the UK.

Educating And Influencing Researchers

Dr Musa Sami, Peter Reynolds

The UK is the most prolific source of research into the harms of cannabis, particularly the tenuous links between cannabis and psychosis.  Despite dozens of studies, mainly from the Institute of Psychiatry at King’s College Hospital, this has never been shown to be any more than statistical correlation.  Most of these studies are confounded by tobacco use but the latest work from Professor Sir Robin Murray and his team shows an even stronger correlation between tobacco and psychosis than cannabis.

Across the world, UK scientists have become notorious for this scaremongering which seems little different from the ‘reefer madness’ hysteria.  To be fair, much of this is down to the UK media which has barely advanced since the 1930s in its reporting.  It provides the environment in which researchers are able to gain funding for research into cannabis harms but hardly ever for cannabis benefits.

CLEAR is now working with the Institute of Psychiatry to develop a new and more balanced way of surveying the effects of cannabis.  Dr Musa Sami has asked us to advise on the construction of a questionnaire on which the Institute will base its future work.

The Facts About CBD In The UK. December 2016.

with 3 comments

oil-dropper-green-bg

On 3rd October 2016 the Medicines and Healthcare products Regulatory Agency (MHRA)  issued notices to a number of CBD suppliers stating that cannabidiol (CBD) was being designated as a medicine and that sale of all CBD products must stop within 28 days, ostensibly by the 1st November.

A lot has happened since.  Most importantly, the Cannabis Trades Association UK (CTAUK) has been established to represent the industry and protect the interests of CBD consumers but there remains great confusion as to the legal status of CBD and whether these products will still be available.  This article sets out the facts and explains how the market is likely to develop. The most important point is that there is no need for panic.  There will be some changes but no one will lose access to CBD for the foreseeable future.

Background

Through the summer of 2016, rumours and half stories had been swirling around about the MHRA taking action on CBD. When the news broke it caused real panic, both for the thousands of people using CBD products and for those working in CBD businesses.  It looked like a real disaster for everyone. On the one hand the government, through the MHRA, was finally recognising the truth that CBD and cannabis are medicine.  On the other, it seemed that the whole industry was going to be shut down, businesses would close, people would lose their jobs and, most importantly, those who rely on CBD products for maintaining their health were going to suffer real harm.  If CBD was going to be regulated as a medicine it would require the investment of hundreds of thousands of pounds to obtain the necessary authorisation to put any products on the market.

It quickly became clear that the MHRA was unprepared for the reaction it received. Its switchboard was swamped by worried callers.  Social media exploded with the inevitable Big Pharma conspiracy theories and even the national press covered the story demonstrating that medicinal cannabis is now an issue of mainstream interest.

ctauk-logoCLEAR took action to rally our friends and colleagues in the legitimate cannabis business and this led to the creation of CTAUK.  The same day the news broke we wrote to the MHRA notifying it of the formation of the trade association and seeking a meeting.

On 13th October, the MHRA issued a statement on its website explaining its actions.

CLEAR’s advisory board members, Professor Mike Barnes issued a statement to the media and Crispin Blunt MP wrote to Dr Ian Hudson, the chief executive of the MHRA.  Even the British Medical Journal covered the story.

On 19th October the MHRA finally confirmed a meeting with the CTAUK to take place on 3rd November.  On 21st October, Dr Ian Hudson replied to Crispin Blunt’s letter.  CTAUK appointed solicitors who in turn obtained counsel’s opinion and on 28th October a solicitor’s letter was sent to the MHRA formally objecting to its action. On 1st November the MHRA updated its statement on its website softening its position by claiming that its notices to CBD suppliers were merely its “opinion” that it should be designated as a medicine.

The meeting took place at MHRA headquarters on 3rd November.  It was cordial and constructive and on 16th November CTAUK wrote to the MHRA formally proposing a system for the regulation of CBD.  Essentially this suggests that CBD products with daily adult dosage of up to 200mg should continue to be marketed as a food supplement.  Products with a daily adult dosage of up to 600mg would require a Traditional Herbal Registration and higher dosage products would require a full Marketing Authorisation.  We await the MHRA’s response.

The MHRA has since written to CBD suppliers requiring them within seven days to provide samples of their products along with various information about them.  However, CTAUK has been able to negotiate that our members have until the end of January to comply.  This is excellent news and demonstrates recognition of the association by the MHRA.

Is CBD Legal In The UK?

Yes, CBD is not a controlled drug under the Misuse of Drugs Act 1971, neither is it covered by the Psychoactive Substances Act 2016.  As long as it is marketed as a food supplement without any medicinal claims it is perfectly legal to sell and to buy.

Is The MHRA Going To Ban CBD?

No, the MHRA will have to assess each product on its own merits, particularly taking into account how it is marketed and whether any claims of medicinal benefit have been made.

What Will Happen In the Future?

We hope that the MHRA will accept our proposals for a system of regulation, meaning that only the highest dose products, such as GW Pharma’s soon-to-be- released ‘Epidiolex’ will require a full Marketing Authorisation.  However, even if the MHRA tries to take formal action about any other products, this is going to take many months and probably a much as a year before anything changes.  We remain confident that we will come to an agreement that will enable everyone to continue to access CBD products.

Guidelines On Cannabis For Medical Professionals.

with one comment

rcgp-external-hq

In a new initiative, CLEAR’s scientific and medical advisor, Professor Mike Barnes, has written to the presidents of several Royal Colleges proposing the development of guidelines around the use of cannabis as medicine.

Professor Mike Barnes

Professor Mike Barnes

This is a tricky situation for doctors.  Surveys and individual reports from CLEAR members indicate that many doctors tacitly endorse their patients’ use of cannabis but clearly cannot recommend the illegal use of cannabis, however safe and effective it may be.

Professor Barnes’ letter refers to the recent APPG report, his own paper ‘Cannabis: The Evidence for Medical Use’ and says:

“…cannabis now has a reasonable evidence base for the management of chronic pain, including neuropathic pain, and the management of spasticity as well as in the management of anxiety and a use in nausea and vomiting in the context of chemotherapy.”

In conjunction with CLEAR, Professor Barnes has written to:

Royal College of Anaesthetists
Royal College of General Practitioners
Royal College of Paediatrics and Child Health
Royal College of Physicians
Royal College of Psychiatrists

His letter goes on to explain that about one million people are using cannabis as medicine:

“I do feel that doctors need guidelines to assist them when patients request advice on the use of cannabis…doctors should be properly informed about harm reduction advice and should be aware of the clinical evidence that is now guiding medicinal use in several other countries around the world.”

Our proposal is for an initial meeting to discuss the idea.  If one or more of the Royal Colleges is prepared to back this initiative, CLEAR will set up and fund a working group of clinicians and medical education specialists to develop a set of guidelines.

 

The British Medical Journal (BMJ) Features The CLEAR Medicinal Cannabis Campaign.

with one comment

By Nigel Hawkes

By Nigel Hawkes

“Muddled thinking” over cannabis leaves patients in limbo, warn campaigners

BMJ 2016; 355 doi: http://dx.doi.org/10.1136/bmj.i5556 (Published 14 October 2016) Cite this as: BMJ 2016;355:i5556

Download PDF here

Companies selling cannabis based products have been told to remove them from the market within 28 days, after a review by the Medicines and Healthcare Products Regulatory Agency (MHRA) determined that they were medicinal products.

Campaigners for cannabis law reform welcomed the recognition that cannabidiol (CBD) had medicinal properties but warned that the MHRA’s action would deprive thousands of users of a product they relied on. They said that it was impossible to obtain marketing authorisation in the timescale given and may never be possible given the high costs of clinical trials and lack of patent protection for a product that contained many components.

“In the long term, it’s a good thing,” said Peter Reynolds of the pressure group CLEAR Cannabis Law Reform. “But my immediate concern is for the tens of thousands of people who use CBD and have become reliant on it. We urgently need interim measures so that supplies can continue.”

The MHRA sent letters on 3 October to 18 companies that sold CBD, saying that it had concluded that CBD met the definition of a medicinal product as defined in the Human Medicines Regulations as “any substance or combination of substances which may be used or administered to human beings either with a view to restoring, correcting, or modifying physiological functions by exerting a pharmacological, immunological, or metabolic action or to making a medical diagnosis.”

This meant, the letter said, that CBD products required a marketing authorisation before they could be sold. Marketing authorisation for drugs requires lengthy clinical trials, only justifiable if the product has patent protection. An alternative route is under the traditional herbal medicines regulations, but that requires evidence that the product has 30 years of use and applies only to minor conditions, where medical supervision is not required. Reynolds said that he thought it unlikely that CBD could qualify by this route.

Mike Barnes, a neurologist and former NHS consultant and chief executive, is clinical adviser to CLEAR. He said, “The decision by the MRHA to treat CBD products as medicines has also been done without thought to the consequences for many thousands of people in the UK who currently benefit from the products. It will have very significant, and in many cases terminal, impact on the many legitimate businesses that provide high quality products.

“The government must now act to sort out their muddled thinking and try to help those people with long term and often painful conditions who benefit from the ready and hitherto legal availability of natural cannabis products. It is ironic that in acknowledging the therapeutic benefits of CBD, the MRHA is effectively suspending access to a product that has enhanced the lives of thousands for many years.”

Crispin Blunt, an MP and CLEAR supporter, has written to the MHRA saying that the decision to designate CBD as a medicine is directly contradicted by the Home Office’s position that cannabis has no medicinal value.

“It is vital that we do not let this anomaly in government policy cause harm to people’s health,” his letter said. He asked for details of how the decision was reached, the consultations undertaken, which specific regulatory regime MHRA proposed for these products, and whether the continued supply of these products, regulated as food supplements, could be ensured until such time that medicinal marketing authorisations could be obtained.

The MHRA has not yet posted details on its website about the decision. In a statement it said that people who used CBD should speak to their GP or other healthcare professional. “We can provide regulatory guidance to any company who may wish to apply for a licence,” the statement added.

The Man From The MHRA. Endangering Public Health With Precipitate Action On CBD.

with 3 comments

Dr Ian Hudson, Chief Executive, MHRA

Dr Ian Hudson, Chief Executive, MHRA

The Medicines and Healthcare Products Regulatory Agency (MHRA) apparent decision to designate cannabidiol (CBD) as a medicine is an unholy mess and has been handled about as badly as it is possible for a government agency to deal with a matter of public safety.

The desk of Dr Ian Hudson, the Chief Executive, will shortly be groaning under the weight of correspondence from MPs asking him to explain exactly what is going on.  We know that the MHRA call centre has been swamped with calls from people desperate for information and in fear that they will be cut off from supplies of the food supplement that is so important for their health.  Many are now being told that no final decision has been taken and everyone is in limbo waiting for some coherent response.  We say “apparent decision” because nothing is clear, no public statement has been issued and anything you have seen in the press is from responses to individuals.

Crispin Blunt, the Conservative MP and a member of the CLEAR advisory board has written to Dr Hudson urging him to meet with CLEAR, Professor Mike Barnes and the newly-formed UK Cannabis Trade Association to discuss what interim arrangements can be put in place.  Tens of thousands of people’s health has been placed in jeopardy and not for trivial matters.  People suffering from serious conditions such as epilepsy, chronic pain, anxiety and Crohn’s Disease have come to rely on CBD products to maintain their health. There are also hundreds of jobs in danger at suppliers providing CBD to the UK market.

We know that many CLEAR members have asked their MP to write to the MHRA seeking clarification.  In Crispin Blunt’s letter he goes further.

“The decision to designate CBD as a medicine is directly contradicted by the Home Office’s position that cannabis has no medicinal value.  It is vital that we do not let this anomaly in government policy cause harm to people’s health. I should be grateful, therefore, if you could explain how the MHRA reached its decision, the consultations it undertook, which specific regulatory regime it proposes for these products and whether the continued supply of these products, regulated as food supplements, can be ensured until such time medicinal marketing authorisations can be obtained.”

CLEAR has received a holding response from the MHRA indicating that a meeting will be arranged and that we will hear by the end of this week. Responsible action from a government agency that is supposed to protect, not endanger public health is urgently needed.